Sign In
Section Navigation
Common TitleNEAR Rwanda
Official Title Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir in Virologically-suppressed HIV-infected Rwandans (Near-Rwanda)
Phase Phase III
ClinicalTrials.gov NCT02104700
Treatments
Rilpivirine-Tenofovir DF-Emtricitabine
Rilpivirine-Tenofovir DF-Emtricitabine Complera

Rilpivirine-Tenofovir DF-Emtricitabine

Tradename:CompleraOther Names:RPV-TDF-FTC, Rilpivirine-Tenofovir disoproxil fumarate-EmtricitabineClass:Single-Tablet Regimens
Categories Treatment-ExperiencedSwitch/Simplification
Funding
IndustryGilead Sciences
References
  • Collins SE, Grant PM, Uwinkindi F, et al. A Randomized Switch From Nevirapine-Based Antiretroviral Therapy to Single Tablet Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed Human Immunodeficiency Virus-1-Infected Rwandans. Open Forum Infect Dis. 2016 Sep;3:ofw141.
    [PubMed Abstract]

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.